**S1 Table. Treatment Regimens and Outcomes in Isoniazid Mono-resistant**

 **Cases (N = 88)**

|  |  |
| --- | --- |
| **Treatment Regimen** | **N (%)** |
|  |  |
| 6 months (N= 71) |  |
| 2HRZ/4HRCureDefaultDeath during treatmentFailure | 18 (25.4%)11 (15.9%)3(4.2%)2 (2.8%)1(1.4%) |
| Recurrence | 2(2.8%) |
| 2HRZE/4HRCureTreatment completionDefaultFailureDeath during treatment | 49 (69%)28 (39.4%)3(4.2%)4(5.6%)4 (5.6%)3 (4.2%) |
| Recurrence | 6 (8.5%) |
| 2HRZE/4HRECureDefaultFailure | 4(5.6%)2(2.8%)1 (1.4%) |
| Recurrence | 1 (1.4%) |
| 7-12 months (N=13) |  |
| 2HRZ/5H2R2CureTreatment completion | 2 (15.4%)1 (7.7 %)1 (7.7 %) |
| 3HRZE/6H3R3 Cure | 1 (7.7 %) |
| 3HRZE/8H3R3Treatment completion | 1 (7.7 %) |
| 3HRZ/4H3R3Cure | 1 (7.7 %) |
| 3HRZE/4H3R3 E6 Cure | 1 (7.7 %) |
| 3HRZE/5H3R3E3Treatment completion | 1 (7.7 %) |
| 3HRZE/6H2R2EDefault | 1 (7.7 %) |
| 3HRZE/6H2R2E4Cure | 1 (7.7 %) |
| 3HRZE/6H3R3E6Cure | 1 (7.7 %) |
| 3HRZE/7H2R2E6Cure | 1 (7.7 %) |
| 3HRZE/8H3R3E6Cure | 1 (7.7 %) |
| 2HRZ /4HR/X3RZ/1S /1ECure | 1(7.7%)1(7.7%) |
| Unknown (N=4) |  |
| Treatment completionDeath during treatmentDid not accept treatmentUnknown | 1 (25%)1 (25%)1 (25%)1 (25%) |

H, isoniazid; R, rifampicin; E, ethambutol; Z, pyrazinamide;

9 patients suffered a subsequent episode (2 after 2HRZ/4HR, 6 after 2HRZE 4HR, and 1 after 2HRZE/4HRE)